A detailed history of Tower Research Capital LLC (Trc) transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 5,314 shares of CRBU stock, worth $10,415. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,314
Previous 39,101 86.41%
Holding current value
$10,415
Previous $64,000 84.38%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.56 - $2.73 $52,707 - $92,238
-33,787 Reduced 86.41%
5,314 $10,000
Q2 2024

Aug 13, 2024

BUY
$1.62 - $5.05 $56,171 - $175,103
34,674 Added 783.24%
39,101 $64,000
Q1 2024

May 15, 2024

SELL
$4.82 - $8.26 $79,563 - $136,347
-16,507 Reduced 78.85%
4,427 $22,000
Q4 2023

Feb 13, 2024

BUY
$3.58 - $6.25 $48,967 - $85,487
13,678 Added 188.51%
20,934 $119,000
Q3 2023

Nov 14, 2023

BUY
$4.08 - $8.14 $1,570 - $3,133
385 Added 5.6%
7,256 $34,000
Q2 2023

Aug 14, 2023

BUY
$4.04 - $5.47 $13,000 - $17,602
3,218 Added 88.09%
6,871 $29,000
Q1 2023

May 09, 2023

SELL
$4.3 - $7.78 $24,226 - $43,832
-5,634 Reduced 60.67%
3,653 $19,000
Q4 2022

Feb 10, 2023

SELL
$5.57 - $11.01 $23,783 - $47,012
-4,270 Reduced 31.5%
9,287 $58,000
Q3 2022

Nov 10, 2022

BUY
$5.34 - $12.79 $56,011 - $134,154
10,489 Added 341.88%
13,557 $143,000
Q2 2022

Aug 15, 2022

SELL
$5.1 - $9.74 $8,226 - $15,710
-1,613 Reduced 34.46%
3,068 $17,000
Q1 2022

May 12, 2022

BUY
$8.42 - $15.32 $17,016 - $30,961
2,021 Added 75.98%
4,681 $43,000
Q4 2021

Feb 14, 2022

BUY
$14.59 - $23.26 $31,952 - $50,939
2,190 Added 465.96%
2,660 $40,000
Q3 2021

Nov 15, 2021

BUY
$15.75 - $30.29 $7,402 - $14,236
470 New
470 $11,000

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $119M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.